Headlines about MEI Pharma (NASDAQ:MEIP) have been trending somewhat negative on Friday, according to Accern. Accern ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a coverage optimism score of -0.06 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.5534769772513 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several equities analysts have weighed in on MEIP shares. Zacks Investment Research downgraded shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Thursday, April 12th. ValuEngine raised shares of MEI Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, February 7th. Oppenheimer set a $7.00 price target on shares of MEI Pharma and gave the company a “buy” rating in a report on Monday, January 8th. Cann reaffirmed a “buy” rating on shares of MEI Pharma in a report on Wednesday, March 21st. Finally, Laidlaw started coverage on shares of MEI Pharma in a report on Thursday, April 12th. They set a “buy” rating and a $7.00 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. MEI Pharma presently has an average rating of “Buy” and a consensus price target of $5.63.
Get MEI Pharma alerts:
NASDAQ:MEIP traded up $0.05 during trading hours on Friday, hitting $2.23. 40,553 shares of the stock traded hands, compared to its average volume of 100,960. MEI Pharma has a 1 year low of $1.55 and a 1 year high of $3.26. The company has a market capitalization of $84.48, a P/E ratio of 31.86 and a beta of 1.89.
MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Thursday, February 8th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.10. MEI Pharma had a negative net margin of 354.10% and a negative return on equity of 42.23%. The business had revenue of $0.36 million for the quarter, compared to the consensus estimate of $1.00 million. research analysts expect that MEI Pharma will post -0.95 EPS for the current year.
About MEI Pharma
MEI Pharma, Inc, an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.